IL-1RN boost or IL-1β blockade through treatment with canakinumab, currently under Phase II trial for the treatment of low and intermediate risk MDS and CML (NTC04239157), reduced to similar extent the expansion of human myeloid cells, in NSG-SGM3 mice. Here, IL1RN is linked to myelodysplastic syndrome.